PRODUCT CATEGORIES
AggRecetin® (Ristocetin) Reagent:
A Trusted Standard for Ristocetin-Induced Platelet Aggregation (RIPA) Testing
Among Bio/Data’s distinguished offerings is AggRecetin® (Ristocetin), a key component for unraveling the intricacies of platelet dynamics. Bio/Data takes pride in presenting Ristocetin in two sizes, ensuring versatility and adaptability in addressing the diverse needs of laboratories engaged in platelet function assessment. This dual-size availability underscores our commitment to providing top-tier diagnostic solutions, enhancing the precision and efficiency of Ristocetin Cofactor Activity Analysis within the diagnostic landscape.
| Product name | AGGRECETIN® 15 mg Ristocetin A Sulfate | AGGRECETIN® 100mg Ristocetin A Sulfate |
| Visual |  |
 |
| Catalog number | 100970 |
101241 |
| Contents | 1 x 15.0 mg AggRecetin
1 x 2.0 mL Diluent |
100mg AggRecetin |
Peak Platelet Precision with Over 90% Ristocetin Purity for Trusted RIPA Testing
AggRecetin Reagent is intended for use in performing routine Ristocetin-Induced Platelet Aggregation (RIPA) testing on Platelet-Rich Plasma (PRP) samples to assess platelet function.
Within the orchestration of platelet dynamics, Ristocetin takes center stage by mediating platelet adhesion (agglutination) through binding to collagen and platelets. It induces the binding of vWF to the Gp1B Platelet Receptor, thereby providing valuable insights into the presence and integrity of the Platelet Glycoprotein (GP) Ibα-V-IX Complex and von Willebrand Factor (VWF) interaction. The Ristocetin CoFactor Activity Assay, conducted with patient Platelet Poor Plasma and fixed platelets, further refines our understanding of the complex interplay governing platelet behavior.
Designed to perform across a range of concentrations, AggRecetin is ideal for both low-dose and high-dose RIPA testing protocols. Low-dose RIPA testing is particularly sensitive for detecting hyper-responsiveness in patients with type 2B vWD and platelet-type vWD (PT-vWD), enabling early and precise identification of these subtypes. High-dose RIPA serves as a valuable confirmatory step, distinguishing between normal platelet function and potential qualitative abnormalities in vWF. This dual utility enhances confidence and helps guide appropriate clinical management.
AggRecetin emerges not only as a reagent of exceptional purity but also as a gateway to deciphering the intricate web of interactions governing platelet function, contributing significantly to our comprehension of hemostatic balance and coagulation dynamics.
- Optimized for RIPA Testing: Delivers reliable platelet aggregation results at both low and high Ristocetin concentrations.
- Low-Dose RIPA Sensitivity: Facilitates detection of hyper-responsiveness in type 2B vWD and PT-vWD patients.
- High-Dose RIPA Confirmation: Verifies normal platelet-vWF interaction or rules out qualitative defects in vWF.
- Supports Targeted Guidelines: Aligns with international guidelines for vWD classification and platelet function evaluation.
- Enables GPIb-vWF Binding Assessment: Reveals abnormalities in platelet receptor binding activity central to vWD pathology.
